Lumanity to Support Translation of PICI’s Breakthrough Science with Go-to-Market Expertise

New strategic alliance aims to accelerate the delivery of novel immunotherapies by aligning scientific innovation with commercial strategy

BOSTON and SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) — Lumanity, a global life sciences strategic services partner, and the Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts, today announced a strategic alliance aimed at accelerating next-generation cancer immunotherapies. By combining PICI’s translational research engine with Lumanity’s development and commercialization expertise, the partnership is designed to ensure that promising scientific breakthroughs reach patients more effectively.

The PICI Network drives progress in immuno-oncology by bringing together nearly 1,000 investigators and a wide range of collaborators across pharma, biotech and non-profits. Through this new alliance, Lumanity will offer targeted development and commercial strategy support to select programs within the PICI Network, including PICI-affiliated efforts advancing toward clinical translation, company formation or commercialization. Areas of collaboration may include disease landscape analysis, indication prioritization, target product profile development and market access strategy.

“Lumanity understands that great science alone isn’t enough—it needs a path to patients,” said Tarak Mody, PhD, Chief Business Officer at PICI. “They bring the commercial fluency and strategic lens needed to turn strong science into strong outcomes—an important part of fulfilling our mission to turn all cancers into curable diseases. Together, we’re strengthening the infrastructure that helps groundbreaking therapies reach patients with a clearer value proposition.”

Bringing a therapy to market today requires more than scientific insight — it also involves navigating regulatory scrutiny, access hurdles and evolving definitions of real-world value. This collaboration is designed to connect early discovery with the strategic foundation needed for effective delivery.

“The industry stands at a crossroads, with groundbreaking technologies presenting both new opportunities and growing complexity,” said Tom Murtagh, Global Practice Lead, Strategy & Insight at Lumanity. “Rising costs, expanding regulatory demands, and a flood of emerging data are all shifting what it takes to deliver credible evidence of value and secure patient access. Meeting that challenge requires a new kind of approach — one that flows seamlessly between early development, evidence generation and stakeholder engagement. That’s what we bring to the table, and we’re excited to work with PICI to shape bold ideas into viable, patient-ready therapies.”

“Across the immuno-oncology landscape, there’s a growing need to align deep scientific insight with real-world delivery,” said Dr. Jeff Bockman, PhD, Executive Vice President and Head of Lumanity’s Oncology Center of Excellence. “PICI’s commitment to decoding the immune system and advancing translational research aligns deeply with our own mission. Together, we hope to guide promising science through the critical decisions that will determine whether it ultimately reaches patients.”

The collaboration is designed to close persistent gaps between discovery, development, and delivery. By focusing on early decisions that shape long-term success, PICI and Lumanity help improve how—and how quickly—innovative immunotherapies reach patients.

The Lumanity and PICI teams are attending the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, held from May 30 to June 3. Please contact us to arrange a meeting at ASCO, or for more information on the partnership.